טוען...
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
BACKGROUND: Pompe disease is a rare, progressive, metabolic disease, and the first treatable inheritable muscle disorder. Enzyme replacement therapy (ERT) with alglucosidase alfa is disease specific and the only medicinal product authorized for the treatment of Pompe disease. Costs of ERT are very h...
שמור ב:
| הוצא לאור ב: | Orphanet J Rare Dis |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5729274/ https://ncbi.nlm.nih.gov/pubmed/29237491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-017-0731-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|